Blackstone Life Sciences committed $250 million to Anagram Therapeutics, backing the company’s oral enzyme replacement therapy program for patients with exocrine pancreatic insufficiency. The funding underscores investor appetite for oral and potentially more scalable enzyme approaches in cystic fibrosis-adjacent care and rare-disease billing realities where access and administration can be limiting.